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Introduction
Sleep apnea (SA), namely, is the absence of oronasal air 
flow during sleep. The pathophysiologic characteristics of 
SA are chronic intermittent hypoxia and sleep fragmenta-
tion [1]. SA is a highly prevalent disorder among adults [2]. 
SA is divided to obstructive sleep apnea (OSA) and central 
sleep apnea (CSA). The former is characterized by recur-
rent collapse of upper airway, whereas the latter is caused 
by the unstable ventilation drive [1, 3]. Abundant evidence 
confirmed that SA is firmly associated with increased risk 
of cardiovascular disease and mortality [4, 5]. Studies also 
suggested that SA might influence the levels of hematocrit 
[6] and blood viscosity [7]. The correlation between SA 
and polycythemia has also been reported [8].
Erythropoietin (EPO) is a glycoprotein hormone which 
is synthesized primarily by the kidney in adult. It is widely 
recognized that EPO may stimulate erythroid stem cells of 
the bone marrow to proliferate and differentiate. EPO has 
also been identified to play an important role in the mecha-
nism of cardiovascular diseases. Robust evidence shows 
that EPO appears to be released in response to hypoxia [9].
Whether the EPO levels in SA patients being changed or 
not remains controversial. Some studies demonstrated that 
EPO concentrations were no different between SA patients 
and normal subjects [10, 11]. In other studies, how-
ever, authors claimed that EPO levels were significantly 
increased in SA subjects [12, 13]. Furthermore, it has been 
suggested that continuous positive airway pressure (CPAP) 
treatment might normalize the diurnal EPO levels in SA 
patients [14].
The primary aim of the present meta-analysis was to 
evaluate the EPO levels in SA patients via quantitatively 
analysis the present available literature.
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Materials and methods
The present meta-analysis was conducted following the 
guideline of the Preferred Reporting Items for Systematic 
reviews and Meta-Analysis (PRISMA) [15].
Search strategy
The electronic databases, namely PubMed, Embase, and 
Web of Science, were searched by using the following 
terms: sleep apnea OR sleep-disorder breathing, and eryth-
ropoietin from inception to May, 4, 2016. No language 
restrictions were applied. References from included studies 
were also perused.
Literature selection criteria
Two reviewers independently selected the available stud-
ies. Studies which met the following criteria were enrolled 
into the present meta-analysis: (1) participants included in 
the study were adults; (2) diagnosis of SA was according 
to polysomnography (PSG); (3) EPO levels were reported 
both in SA group and control group. Editorials, reviews, 
case reports, congress articles, and animal studies were 
excluded. An email to the corresponding author was writ-
ten if the essential data of study was ambiguous or not pre-
sented. After two no response attempt, the study was also 
ruled out. The consensus was obtained through a meeting 
with all authors if any discrepancy were presented between 
the two reviewers.
Literature quality and data extraction
Evidence level was defined in accordance with Oxford 
Centre for Evidence-based Medicine (CEBM)-Levels of 
Evidence [16, 17]. The data of the included articles were 
extracted by two reviewers independently. The following 
items were listed: first author, publication year, country, 
sample size, and the clinical characteristics of the par-
ticipants, such as age, male percentage, body mass index 
(BMI), complications, PSG parameters and EPO levels in 
each group.
Statistical analysis
Stata version 12.0 and Review Manager 5.2 were applied 
for statistical analysis. The I2 was obtained to express 
the heterogeneity between studies. If I2 > 50%, indicating 
that moderately or highly heterogeneous existed, a ran-
dom effects model was conducted to estimate the effect 
size (Standard mean difference, SMD; 95% confidence 
interval, 95% CI); if I2 ≤ 50%, fixed-effects model was 
used to obtain the weighted mean difference (WMD, 95% 
confidence interval, 95% CI) [18]. Furthermore, subgroup 
analysis was performed to assess the influence of gender, 
BMI, AHI, cardiovascular disease, and time of exsangui-
nate blood on EPO levels. Since these variables of other 
type of SA [19, 20] and ODI value [21, 22], were only 
reported in two included studies, subgroup analysis were 
not performed stratified by these two variables. Sensitiv-
ity analysis was also conducted to evaluate the influence 
of each study on overall effect size. Potential publication 
bias was showed with funnel plot, and tested by Begg’s 
test and Egger’s test [23]. Statistical significance was 
confirmed if p value <0.05.
Results
Literature search
A total of 405 studies were identified by electronic search 
for initial scrutiny. After removing duplicated records 
and reviewing the titles and abstracts, 24 studies were 
considered worthy of further full-text scrutiny. Of the 
24 studies, 15 studies were subsequently excluded (see 
detail in Fig. 1). Finally, 9 studies [10–13, 19–21, 24, 25] 
involving 407 participants were included into the present 
meta-analysis.
Characteristics of included studies
Tables  1 and 2 outline the characteristics of the subjects 
in each study. The evidence levels were 2b (both evidence 
levels and recommendation grade were moderate accord-
ing to CEBM) in all studies. Sample size in each study 
was relatively small (less than 100). The predominant type 
of SA was obstructive sleep apnea (OSA) in most of the 
included studies. Except for one study, all SA patients in 
the included studies suffered severe SA (the apnea hypo-
pnea index was  more than 30 events/h). The exact EPO 
data in one study was obtained via contacting the corre-
sponding author [25].
Pool analysis of the difference in EPO between SA 
group and control group
As the I2 (80.2%) was significantly high, obviously hetero-
geneous existed between studies, thus random effect model 
was conducted to explore the difference in EPO between 
groups. Figure 2 illustrates that EPO levels in the SA group 
were significantly higher than that in control group (SMD 
0.61, 95% CI 0.11–1.11, p = 0.016).
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Subgroup analysis stratified by various clinical 
parameters
Table 3 outlines the subgroup analysis stratified by different 
parameters. Results showed that there were significantly 
higher EPO levels in patients with BMI <30  kg/m2, and 
cardiovascular complications. EPO levels were increased 
in patients with SA regardless of AHI levels. Gender, and 
exsanguinate time had no influence on EPO in the further 
subgroup analysis.
Sensitivity analysis
Sensitivity analysis showed that individual study had no 
influence on the overall effect size (Fig. 3).
Publication bias
Figure  4 shows that publication bias seem to exist, how-
ever, both Begg and Egger tests proved that no publica-
tion bias existed in the present study (p = 0.293 and 0.466, 
respectively).
Discussion
The present meta-analysis with 9 studies involving 407 
participants demonstrated that, compared with normal 
subjects, EPO levels were increased in patients with SA, 
especially in those with low BMI, and cardiovascular 
complications. 
EPO, a glycoprotein hormone with 30.4  kDa relative 
molecular mass, is composed of 165 amino acids. It is 
mainly produced by the kidney and liver in adult [26]. 
EPO can bind to erythroid progenitor cell surface recep-
tor, then leading to the activation of several signal path-
ways, such as the Ras/mitogen-activated kinase pathway, 
etc [27]. After stimulation of certain genes expression, 
erythropoietic progenitor cells can proliferate and dif-
ferentiate to mature red blood cells. The vital function of 
EPO is of regulation the blood oxygen levels via adjust-
ing the circulating erythrocytes number [26]. Diurnal 
variation of serum EPO levels can be detected in normal 
Fig. 1  Study flow diagram
Table 1  Characteristics of included studies
SA sleep apnea
Study no. Author Publication year Country Study design Evidence level Sample size
SA group Control group
1 McKeon 1990 Australia Cross section 2b 23 36
2 Cahan 1992 USA Cross section 2b 12 9
3 Pokala 1995 USA Cross section 2b 8 8
4 Imagawa 2001 Japan Cross section 2b 41 45
5 Wang 2004 China Cross section 2b 18 16
6 Ryan 2005 Ireland Cohort study 2b 19 14
7 Calvin 2010 Chile Cross section 2b 14 15
8 Cifitci 2011 Turkey Cohort study 2b 69 17
9 Kukwa 2013 Poland Cross section 2b 14 23
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subjects: the nadir occurred at daytime, the peak concen-
tration happened early in the morning, but this phenom-
enon could not be observed in chronic obstructive pulmo-
nary disease [28, 29].
Serum levels of EPO can be influenced by various fac-
tors. The most important one is hypoxia. Evidence showed 
that elevated serum EPO levels are an adaptive response of 
human body to hypoxia. A previous study indicated that 
Fig. 2  Pool analysis of the difference in EPO between SA group and control group
Table 3  Results of subgroup 
analysis
WMD weighted mean difference, CI confidence interval, BMI body mass index, OSA obstructive sleep 
apnea, CSA central sleep apnea, SDB sleep-disorder breathing
Subgroup No. of study Heterogeneity WMD
I2 p WMD (95% CI) p
Gender
 Male 4 70.4 0.000 0.35 (−0.28–0.98) 0.279
 Male and female 4 88.0 0.000 0.93 (−0.22–2.08) 0.111
BMI ≥30 kg/m2 in OSA group
 Yes 4 0.0 0.399 −0.01 (−0.32–0.30) 0.930
 No 2 80.3 0.024 1.90 (0.57–3.24) 0.005
AHI ≥30 events/h
 Yes 8 60.9 0.012 0.38 (0.02–0.75) 0.040
 No 1 – – 2.61 (1.70–3.51) 0.000
Cardiovascular disease
 Yes 3 70.8 0.033 1.63 (0.71–2.55) 0.001
 No 4 56.5 0.075 0.16 (−0.30–0.61) 0.501
Time of exsanguinate blood
 Morning 5 73.9 0.004 0.53 (−0.09–1.14) 0.092
 Evening 1 – – −0.22 (−1.2–0.77) 0.664
 Morning and evening 1 – – 0.14 (−0.39–0.66) 0.604
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COPD patients, characterized by sustained hypoxia, had 
elevated serum EPO levels [30]. The pathophysiological 
mechanism of intermittent hypoxia is similar to ischemia/
reperfusion injury. Several studies indicated that pre-expo-
sure to intermittent hypoxia can protect the myocardial tis-
sue against ischemia/reperfusion injury [31, 32]. Similarly 
to sustained hypoxia, intermittent hypoxia has also been 
found to play a magnificent role in the regulation of EPO 
levels. An experimental study illustrated that EPO was 
increased significantly when rats were exposed to intermit-
tent hypoxia for 1–3 weeks [33]. The vital pathophysiologi-
cal characteristic of SA is intermittent hypoxia. However, 
whether the EPO levels are increased or not in SA patients 
remained controversial. In addition, some interventional 
studies on the effect of CPAP treatment on EPO levels have 
shown contradictory results. Cahan et al. [14] showed that 
CPAP treatment might attenuate diurnal EPO levels in SA 
patients. A study by Ryan and coworkers [25] demonstrated 
that the EPO levels in OSA patients had no alternation after 
6 weeks of CPAP treatment. Multicenter, randomized-con-
trol interventional study is needed to clarify the definitive 
effect of CPAP on EPO levels.
The subgroup analysis of the present study indicated that 
SA patients with cardiovascular disease had significantly 
higher EPO levels. We speculated that elevated EPO lev-
els in patients with SA and cardiovascular disease were an 
adaptive response against intermittent hypoxia [31]. Previ-
ous studies claimed that EPO levels had diurnal variation 
[12, 24]. The present meta-analysis was inconsistent with 
those studies, in that we could not observe the circadian 
fluctuation of EPO in SA patients. We also failed to explain 
the phenomenon that when compared to patients with 
high BMI, EPO was increased in patients with low BMI. 
The low numbers of included studies and small sample 
size might partly contribute to those phenomena. Further 
Fig. 3  Sensitivity analysis
Fig. 4  Publication bias
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investigation is required to clarify those aforementioned 
phenomena.
Several limitations of the present meta-analysis should 
be emphasized. First, the most significant limitation was 
the severe heterogeneity between included studies, show-
ing a high variation of the results among each study. Sec-
ond, the individual study is relatively low-level evidence. 
Third, although a highly sensitive search strategy for the 
potentially eligible studies was applied, some studies may 
still be overlooked. Fourth, the relative small sample size 
of each included study might restrict the generalizability 
of the results. Fifth, except two included studies [19, 20] 
(subjects in one study was CSA, the other one was sleep-
disorder breathing), subjects in the most remain studies 
were OSA, it was difficult for us to evaluate the influence of 
SA type on serum EPO levels. Finally, although statistical 
significance was not observed, it was still hard to rule out 
the publication bias.
In conclusion, the present meta-analysis confirmed 
that elevated EPO levels were found in SA patients. We 
speculated that increased EPO might be associated with 
increased risk of subsequent cardiovascular diseases in SA 
patients.
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